Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran.
Formerly, Ankara Yildirim Beyazit University, Ankara, Turkey.
J Biomol Struct Dyn. 2022 Oct;40(16):7629-7644. doi: 10.1080/07391102.2021.1899050. Epub 2021 Mar 22.
The recent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), positive-sense RNA viruses, originated from Wuhan City in December 2019 and propagated widely globally. Hence, the disease caused by this virus has been declared as a global pandemic by the WHO. As of 18th February 2021, at least seven different vaccines across three platforms have been rolled out in countries and more than 200 additional vaccine candidates have been in development, of which more than 60 are at the stage of the clinical development. So far, Most of the approved vaccine manufacturers are Pfizer, AstraZeneca, and Serum Institute of India, which have been finalized by WHO. Synthetic drug-associated complications have evoked scientific attention for natural product-based drugs. There has been a surge in the antiviral compounds from natural resources along with some therapies. Cyanobacteria are the fruitful reservoir of many metabolites like sulfated polysaccharides and lectins that possess strong antiviral activities and immunity boosting effects. However, the research in this field has been relatively under-developed. The current research highlights important features of cyanobacterial antiviral biomaterials, benefits and drawbacks of cyanobacterial drugs, challenges, future perspectives as well as overview of drugs against COVID-19. In addition, we have described mutated variants and transmission rate of coronaviruses. The current research suggests that cyanobacterial species and their extracts have promising applications as potentially antiviral drug biomaterials against COVID-19. Communicated by Ramaswamy H. Sarma.
新型严重急性呼吸系统综合症冠状病毒 2（SARS-CoV-2），一种正链 RNA 病毒，起源于 2019 年 12 月的武汉市，并在全球范围内广泛传播。因此，世界卫生组织宣布由该病毒引起的疾病为全球性大流行。截至 2021 年 2 月 18 日，至少有来自三个平台的七种不同疫苗在各国推出，超过 200 种额外的候选疫苗正在开发中，其中超过 60 种处于临床开发阶段。到目前为止，大多数获得批准的疫苗制造商是辉瑞、阿斯利康和印度血清研究所，这些疫苗已被世界卫生组织敲定。与合成药物相关的并发症引起了科学界对天然产物药物的关注。随着一些疗法的出现，来自自然资源的抗病毒化合物也大量涌现。蓝藻是许多代谢物的丰富来源，如硫酸多糖和凝集素，它们具有很强的抗病毒活性和免疫增强作用。然而，该领域的研究相对较少。目前的研究强调了蓝藻抗病毒生物材料的重要特征、蓝藻药物的优缺点、挑战、未来展望以及针对 COVID-19 的药物概述。此外，我们还描述了冠状病毒的突变变体和传播率。目前的研究表明，蓝藻物种及其提取物作为对抗 COVID-19 的潜在抗病毒药物生物材料具有广阔的应用前景。由拉马萨米·H·萨尔马传达。
